Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

22. April 2026 07:30 ET | Quelle: CervoMed Inc.

CervoMed Announces New Data at the 2026 AAN Annual Meeting that Demonstrated Neflamapimod Increased Basal Forebrain Volume and Functional Connectivity in Dementia with Lewy Bodies

Results consistent with pre-clinical studies demonstrating that, in the early stages of the neurodegenerative process, disease progression in the basal forebrain is reversible Findings also correlate...
21. April 2026 16:30 ET | Quelle: Rapport Therapeutics, Inc.

Rapport Therapeutics Presents RAP-219 Focal Onset Seizure Phase 2a Follow-up Period Results Demonstrating Sustained Seizure Reduction at the 2026 American Academy of Neurology Annual Meeting

Clinically meaningful efficacy demonstrated in the 8-week follow-up period (weeks 9-16), with a 90% median reduction in clinical seizures over baseline in weeks 9-12 and a 59% median reduction in...
01. April 2026 07:00 ET | Quelle: Rapport Therapeutics, Inc.

Rapport Therapeutics to Present New Phase 2 Treatment Follow-Up Data for RAP-219 in Focal Onset Seizures at the 2026 American Academy of Neurology Annual Meeting

BOSTON and SAN DIEGO, April 01, 2026 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery and...
21. März 2025 07:00 ET | Quelle: Rapport Therapeutics, Inc.

Rapport Therapeutics to Present Data at the 2025 American Academy of Neurology Annual Meeting

Rapport will present two encore posters at the American Academy of Neurology Annual Mtg - data on RAP-219, which is in current Ph2a trial in focal epilepsy
01. April 2022 07:00 ET | Quelle: Clene, Inc.

Updated Interim Data from Clene Nanomedicine’s RESCUE-ALS Open-Label Extension Study to be Presented in Emerging Science Program at 2022 AAN Annual Meeting

SALT LAKE CITY, April 01, 2022 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ: CLNN) along with its subsidiaries “Clene” and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage...